Neuropeptide S vs Efinopegdutide
Head-to-head comparison of Neuropeptide S (Neuropeptide S) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Neuropeptide S | Efinopegdutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Neuropeptide S | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 2203 Da | N/A |
| Half-Life | Minutes to <1 hour | Approximately 1 week |
| Amino Acids | 20 | N/A |
| Typical Dose | Research-only; no validated human dose | Trial-dependent; weekly SC dosing |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 14 |
| Research Status | Pre-clinical | Clinical |
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.